Webinar: Unlocking Smarter Antibody Selection Strategies

Many promising antibody therapeutics fail in development due to poor biophysical properties that can impact PK, stability, and manufacturability. This webinar presents an integrated strategy for early-stage developability assessments utilizing comprehensive in vitro and in silico toolkits. Discover how Alloy Therapeutics leverages a benchmark dataset of 160 clinical-stage antibodies to guide smart selection during discovery and accelerate lead optimization.

In this on-demand webinar, you will learn:

• Why early-stage developability assessments are essential for downstream success
• How in vitro assays relate to critical attributes such as polyreactivity
• Best practices for validating and normalizing assay data using clinical-stage benchmarks
• How to integrate in-silico tools to streamline workflows and efficiently prioritize lab resources.

Dalton Markrush and Lucy Liu share how integrated workflows enable smarter triage, faster optimization, and the delivery of highly developable antibody leads. 

Download now to access the webinar and learn how Alloy accelerates optimization and delivers highly developable antibody leads.